Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand
PositiveFinancial Markets
Eli Lilly has raised its annual revenue guidance, reflecting the strong demand for its weight-loss drug. This increase is significant as it highlights the growing market for obesity treatments and the company's ability to capitalize on this trend. Investors and stakeholders are optimistic about the potential for continued growth, making this a noteworthy development in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System











